Regeneron's Next-Gen Monoclonal Antibody Revealed

Regeneron Pharmaceuticals, Inc. discretely revealed its intentions to expand its Anti-SARS-CoV-2 Monoclonal Antibody offerings at the J.P. Morgan Healthcare Conference on January 9, 2023.

Regeneron's presentation stated that in the U.S. alone, millions of immuno-compromised people will not adequately respond to vaccination.

And antibodies can be dosed prophylactically to prevent infection and severe COVID-19 disease.

On slide #27, the Company stated its 'Next-gen COVID antibody binds outside variable RBD and has demonstrated high neutralization activity against all known variants and lineages and disclosed it anticipates initiating the REGN14287 phase 3 clinical trial in 2023, pending regulatory discussions.

The NCT04425629 study was last updated on July 29, 2022.

Previously Regeneron's first-generation REGEN-COV monoclonal antibody combination (casirivimab and imdevimab) is U.S. Food and Drug Administration-approved and was a market leader in the U.S.

The U.S. NIH stated on December 1, 2022, vaccination remains the most effective way to prevent SARS-CoV-2 infection and should be considered the first line of prevention.